Real-world experience with pembrolizumab in patients with advanced melanoma: A large retrospective observational study.
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antineoplastic Agents, Immunological
/ therapeutic use
Female
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Longitudinal Studies
Male
Melanoma
/ drug therapy
Middle Aged
Retrospective Studies
Survival Rate
Time Factors
Treatment Outcome
Young Adult
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
entrez:
27
7
2019
pubmed:
28
7
2019
medline:
2
8
2019
Statut:
ppublish
Résumé
Pembrolizumab has been approved in the United States for treating advanced melanoma for >4 years. We examined real-world pembrolizumab use and associated outcomes in US oncology clinical practices, including patients who would not be eligible for clinical trials.Flatiron Health longitudinal database was used to identify adult patients with advanced melanoma initiating ≥1 dose of pembrolizumab from September 4, 2014, through December 31, 2016, with follow-up through December 31, 2017. Patients in any clinical trial during the study period were excluded. Overall survival (OS) and time on treatment from pembrolizumab initiation were analyzed using the Kaplan-Meier (KM) method. Subgroup analyses were conducted to examine OS for several patient characteristics including Eastern Cooperative Oncology Group (ECOG) performance status >1, brain metastases, and corticosteroids before pembrolizumab initiation.Pembrolizumab was administered to 315 (59%), 152 (29%), and 65 (12%) patients as first-, second-, and third-line/later therapy. Median age at pembrolizumab initiation was 68 years (range, 18-84); most patients were male (66%) and white (94%). Of those with available data, 38% had BRAF-mutant melanoma, 21% had elevated lactate dehydrogenase (LDH) level, and 23% had ECOG >1. Overall, 18% had brain metastases, and 23% were prescribed corticosteroids <3 months before initiating pembrolizumab. Median study follow-up was 12.9 months (range, 0.03-39.6). Median OS was 21.8 months (95% confidence interval [CI] 16.8-29.1); KM 1-year and 2-year survival rates were 61% and 48%, respectively; and median time on pembrolizumab treatment was 4.9 months (95% CI 3.7-5.5). Median OS for first-line pembrolizumab was not reached, and for second-line and third-line/later was 13.9 and 12.5 months, respectively (log-rank P = .0095). Significantly better OS (all P ≤.0014, log-rank test) was evident for patients with ECOG performance status (PS) of 0 to 1 (vs >1), normal (vs elevated) LDH level, and no (vs yes) corticosteroid prescription <3 months before. No difference was recorded in OS by brain metastases (log-rank P = .22) or BRAF mutation status (log-rank P = .90).These findings support effectiveness of pembrolizumab in the real-world clinical setting and provide important insights into patient characteristics and outcomes associated with pembrolizumab therapy for a heterogeneous patient population with advanced melanoma, including patients who would not be eligible for clinical trials.
Identifiants
pubmed: 31348273
doi: 10.1097/MD.0000000000016542
pii: 00005792-201907260-00048
pmc: PMC6709121
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
pembrolizumab
DPT0O3T46P
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16542Références
J Clin Oncol. 2018 Jul 1;36(19):1905-1912
pubmed: 29746230
J Clin Oncol. 2015 Jun 20;33(18):2092-9
pubmed: 25918278
Future Oncol. 2016 May;12(10):1261-74
pubmed: 27096309
JAMA Dermatol. 2018 Jan 1;154(1):82-87
pubmed: 29214290
J Immunother Cancer. 2018 Jan 23;6(1):8
pubmed: 29357948
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Cancer Immunol Immunother. 2018 Oct;67(10):1571-1578
pubmed: 30056599
BMC Cancer. 2018 Feb 6;18(1):145
pubmed: 29409500
Ann Intern Med. 2018 Jan 16;168(2):121-130
pubmed: 29297009
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Melanoma Res. 2017 Aug;27(4):358-368
pubmed: 28509765
J Immunother. 2017 Apr;40(3):108-113
pubmed: 28221189
J Clin Oncol. 2013 Feb 1;31(4):499-506
pubmed: 23248252
Br J Cancer. 2014 Feb 4;110(3):551-5
pubmed: 24495873
Lancet. 2017 Oct 21;390(10105):1853-1862
pubmed: 28822576
Br J Cancer. 2017 Jun 6;116(12):1558-1563
pubmed: 28524161
JAMA Oncol. 2018 Aug 1;4(8):e180798
pubmed: 29800974
Clin Cancer Res. 2018 Oct 15;24(20):4960-4967
pubmed: 29685882
J Immunother Cancer. 2017 Oct 17;5(1):76
pubmed: 29037215
J Clin Oncol. 2000 Nov 15;18(22):3782-93
pubmed: 11078491
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Melanoma Res. 2019 Jun;29(3):289-294
pubmed: 30520799
Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):152-160
pubmed: 29395837
Lancet. 2014 Mar 1;383(9919):816-27
pubmed: 24054424
Eur J Cancer. 2017 Mar;74:89-95
pubmed: 28335891
Melanoma Res. 2017 Oct;27(5):519-523
pubmed: 28817445
J Immunother Cancer. 2015 Aug 18;3:36
pubmed: 26288737
Melanoma Res. 2018 Dec;28(6):489-490
pubmed: 30371570
JAMA. 2016 Apr 19;315(15):1600-9
pubmed: 27092830
Oncologist. 2017 Aug;22(8):963-971
pubmed: 28476944
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Br J Cancer. 2016 Feb 2;114(3):256-61
pubmed: 26794281
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
Future Oncol. 2019 Feb;15(5):459-471
pubmed: 30251550
J Immunother Cancer. 2018 May 9;6(1):32
pubmed: 29743104
J Immunother. 2018 Feb/Mar;41(2):86-95
pubmed: 29252916
Lancet Oncol. 2016 Jul;17(7):976-983
pubmed: 27267608
J Immunother Cancer. 2018 Apr 4;6(1):26
pubmed: 29618381
Ann Oncol. 2019 Apr 1;30(4):582-588
pubmed: 30715153
Future Oncol. 2018 Jan;14(1):5-8
pubmed: 29052448
N Engl J Med. 2018 Aug 23;379(8):722-730
pubmed: 30134131
J Clin Oncol. 2018 Jun 10;36(17):1668-1674
pubmed: 29283791